Research Article
C-Reactive Protein as a Prognostic Biomarker for Gynecologic Cancers: A Meta-Analysis

Yingying Yang,1 Xiu Li,1 Hui Qian,2 Guangci Di,1 Ruhua Zhou,3 Yuwei Dong,2 Wenyue Chen,1 and Qingling Ren1

1Department of Gynaecology, Affiliated Hospital of Nanjing University of Chinese Medicine, No. 155, Hanzhong Street, Nanjing 210029, Jiangsu, China
2Department of Gastroenterology, Affiliated Hospital of Nanjing University of Chinese Medicine, No. 155, Hanzhong Street, Nanjing 210029, Jiangsu, China
3Nursing Institute of Nanjing Medical University, No. 818, Tianyuan Street, Nanjing 210029, Jiangsu, China

Correspondence should be addressed to Qingling Ren; yfy0047@njucm.edu.cn

Received 23 July 2022; Revised 3 September 2022; Accepted 14 September 2022; Published 11 October 2022

Academic Editor: D. Plewczynski

Copyright © 2022 Yingying Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. The prognostic role of CRP (C-reactive protein) in gynecological tumors has been previously reported in individual studies, but whether CRP can be used as a separate potential prognostic factor has not been systematically reviewed. The purpose of this research is to determine if there is a link between CRP levels and the prognosis of gynecological cancer patients. Methods. A systematic search was carried out to find the literature evaluating the predictive role of CRP in the prognosis of gynecological cancer patients. For the purpose of determining the relationship between CRP and clinicopathological characteristics, the pooled odds ratio (OR) was calculated. A hazard ratio (HR) with a 95% confidence interval (CI) was used to determine differences in overall survival (OS), disease-free survival (DFS), or progression-free survival (PFS) between patients with low and high CRP levels. Results. A total of 19 studies, including 4062 patients, were analyzed retrospectively. The FIGO stage was related to the CRP level (OR = 0.43, 95% CI: 0.19–1.00). Age, lymph node metastasis, and histological grade were not associated with CRP level (OR = 0.93, 95% CI: 0.69–1.25; OR = 0.91, 95% CI: 0.65–1.28; OR = 0.74, 95% CI: 0.52–1.05). Worse OS (HR = 1.40, 95% CI: 1.23–1.57), DFS (HR = 1.20, 95% CI: 1.12–1.28), and PFS (HR = 1.57, 95% CI: 1.23–1.91) were associated with elevated CRP levels, as shown by the pooled results. Subgroup analysis was performed according to cancer type (endometrial cancer: HR = 1.15, 95% CI: 1.02–1.28; ovarian cancer: HR = 1.67, 95% CI: 1.03–2.31; cervical cancer: HR = 1.42, 95% CI: 1.19–1.64), multivariate value (HR = 1.22, 95% CI: 1.10–1.33), and age (HR = 1.50, 95% CI: 1.28–1.72). Significant correlations were observed between CRP and OS. Conclusions. CRP may be utilized as a prognostic indicator for a variety of gynecologic malignancies, including cervical cancer, ovarian cancer, endometrial cancer, and vulvar cancer.

1. Introduction

In 2020, there have been more than 135000 verified instances of three main gynecological malignancies worldwide. These include cervical cancer, ovarian cancer, and endometrial cancer. The fourth most common cause of cancer-related mortality in women is cervical cancer. [1]. Chinese and Indian cases account for one-third of the total in the world [2]. The incidence and mortality of cervical cancer will decrease due to the extensive implementation of the cytology screening programs. Ovarian cancer is the seventh most frequent female cancer in the world, according to the World Health Organization. In 2020, there emerged 310000 new cases of ovarian cancer and 210000 deaths worldwide. Ovarian cancer has a morbidity of 1/75 and mortality of 1/100 [3]. Ovarian cancer is usually diagnosed at its advanced stage, which leads to high mortality. The five-year relative survival rate is barely 29%. Approximately 15% of cases are identified as localized cancers (stage 1), with a 5-year survival rate of 92%. Globally, the 5-year relative survival rate is
between 30% and 40%, with just a little improvement (2–4%) since 1995 [4]. In 2021, 420,000 new cases of endometrial cancer were reported worldwide [5]. The incidence and mortality of endometrial cancer have been progressively rising in most developed nations, mostly as a result of changes in lifestyle, the aging population, and socioeconomic factors. Gynecological cancers are mainly treated with surgery, radiotherapy, chemotherapy, biological, and targeted drugs. Postoperative markers, which include histopathological grade, lymph node status, and invasion depth, are viewed as vital indicators of the progression and recurrence of gynecological cancers [6]. However, radiotherapy and chemotherapy pose a high toxic burden and an economic cost. Therefore, more biomarkers should be explored to reform the current treatment strategies.

The role of chronic inflammation in carcinogenesis has been widely studied. The relationship between inflammation and tumorigenesis was first proposed by Rudolph Virchow in 1863 [7]. Furthermore, several inflammatory indicators, such as C-reactive protein (CRP), have been shown to be able to predict the prognosis of some cancers, including gastric cancer and lung cancer [8]. Recent research has confirmed that serum CRP levels are positively related to the degree of malignancy [9–18].

CRP is a protein that is produced by hepatocytes during the acute phase of an inflammatory response. Its level rises sharply to remove pathogens and activate the complement system. Many malignant tumors occur in chronically infected tissues, and 15–20% of human tumors are related to inflammation [12]. Patients with malignant tumors may have a rise in serum CRP levels, which may be associated with the proliferation of tumor cells and the generation of inflammatory substances in the body. Some proinflammatory cytokines, such as IL-6 and IL-11, can stimulate the expression of CRP, resulting in an increase in serum CRP levels [13–16].

Higher CRP levels have been shown to be associated with a worse prognosis in a range of malignant tumors, including lung cancer, gastric cancer, and hepatic cancer. [17, 18]. However, its prognostic value in gynecological cancer is not clear. Therefore, the goal of this meta-analysis was to determine whether or not CRP affects a patient’s prognosis after being diagnosed with gynecology cancer.

2. Materials and Methods

2.1. Data Collection. PubMed, Web of Science, and Embase were used to search for studies on CRP and gynecological cancer published before June 1, 2022. The following key words were used for literature retrieval: (“CRP” or “C-reactive protein”) and (“gynecologic” or “cervix uteri” or “corpus uteri” or “ovary” or “endometrium” or “vagina” or “vulva” or “fallopian tube” or “gynecological” or “cervical” or “ovarian” or “endometrial” or “vulvar” or “vaginal” or “GTD”), and (“tumor” or “carcinoma” or “cancer”). Additionally, the references in the obtained papers were scrutinized to find any other relevant research outside of these two key phrases in the query. The literature retrieval flowchart is shown in Figure 1.

2.2. Inclusion Criteria. Inclusion criteria were those studies in which (a) the postoperative pathological diagnosis of gynecologic cancer was made; (b) the serum CRP prior to
### Table 1: Main characteristics of studies included in this meta-analysis.

| First author, publication year | Country  | Recruitment period | Age (mean/median) yr | No. pts | Cancer type | Pathology | Stage | Survival analysis | Mean/median months of follow-up | NOS scores |
|--------------------------------|----------|--------------------|----------------------|---------|-------------|-----------|-------|-------------------|--------------------------------|-------------|
| Schmid et al. 2007 [36]        | Austria  | 1995–2005          | NM                   | 403     | EC          | ADC       | FIGO I-IV | OS,DDFS           | NM                             | 6           |
| Six et al. 2008 [33]           | Austria  | 1995–2003          | 69.1                 | 67      | VC          | SCC       | FIGO I-IV | OS,DDFS           | NM                             | 7           |
| Heffler et al. 2008 [28]       | Austria  | NM                 | 60.5                 | 623     | OC          | Serous, mucinous, endometrioid, clear cell, and others | FIGO I-IV | OS               | 25.5                           | 7           |
| Stephan et al. 2011 [23]       | Austria  | 2000–2009          | 49.2                 | 178     | CC          | SCC and non-SCC | FIGO I-IV | OS,DDFS           | 46                             | 8           |
| Dobrzycella et al. 2013 [27]   | Poland   | 2003–2007          | 57.6                 | 118     | OC          | Serous, mucinous, endometrioid, clear cell, and others | FIGO I-IV | OS,DDFS           | 24.63                          | 8           |
| Nakamura et al. 2015 [21]      | Japan    | 2005–2014          | 52.6                 | 32      | CC          | SCC and non-SCC | NM       | OS               | NM                             | 7           |
| Zhang et al. 2015 [29]         | China    | 2000–2012          | 50.6                 | 190     | OC          | Serous, mucinous, endometrioid, clear cell, and others | FIGO I-IV | OS,PFS            | 43                             | 8           |
| Lu et al. 2015 [31]            | China    | 2006–2010          | 55.28                | 107     | OC          | SCC       | FIGO I-IV | OS               | 28.5                           | 8           |
| Li et al. 2015 [34]            | China    | 2007–2009          | 53                   | 282     | EC          | Endometrioid and others | FIGO I-IV | DSS              | 51.2                           | 8           |
| Xiao et al. 2015 [26]          | China    | 2004–2011          | 52                   | 238     | CC          | SCC, non-SCC | FIGO IB1-IVA | OS,PFS | 42                             | 8           |
| Bodner–Adler et al. 2016 [19]  | Austria  | 2005–2015          | 51                   | 46      | CC          | ADC       | FIGO I-IV | OS               | NM                             | 7           |
| Liu et al. 2017 [32]           | China    | 2006–2012          | 53                   | 200     | OC          | Serous, mucinous, endometrioid, clear cell, and others | FIGO I-IV | OS               | NM                             | 8           |
| He et al. 2018 [25]            | China    | 2007–2009          | 69                   | 198     | CC          | SCC       | FIGO I-IV | OS               | NM                             | 8           |
| Wang et al. 2019 [24]          | China    | 2012–2014          | 51.5                 | 110     | CC          | SCC       | FIGO I-I   | OS,PFS            | NM                             | 8           |
| Wang et al. 2020 [20]          | China    | 2013–2015          | 59                   | 150     | CC          | SCC       | FIGO IB2, IIA2, III | OS               | 39                             | 8           |
| An et al. 2020 [22]            | China    | 2010–2017          | 45.5                 | 278     | CC          | SCC, non-SCC | FIGO IB-I | OS,PFS            | NM                             | 8           |
| Terlikowska et al. 2020 [35]   | Poland   | 2006–2012          | 69                   | 176     | EC          | ADC       | FIGO I-IV | OS               | NM                             | 7           |
| Komura et al. 2020 [30]        | Japan    | 2007–2016          | NM                   | 308     | OC          | Serous, mucinous, endometrioid, clear cell, and others | FIGO I-IV | DSS              | NM                             | 6           |
| Njoku et al. 2021 [37]         | United Kingdom | 2010–2015   | 66                   | 358     | EC          | Endometrioid and others | FIGO I-IV | OS,PFS            | 40                             | 8           |

Abbreviations: ADC: adenocarcinoma; CC: cervical cancer; DFS: disease-free survival; DSS: disease-specific survival; EC: endometrial cancer; FIGO: International Federation of Gynecology and Obstetrics; NM: not mentioned; OC: ovarian cancer; OS: overall survival; PFS: progress-free survival; RFS: recurrence-free survival; SCC: squamous cell carcinoma; VC: vulvar cancer.
Table 2: HRs and 95% CIs of patient survival or cancer progression in association with CRP in eligible studies.

| First author, publication year | Cut-off value (mg/L) | PFS/DFS/RFS/DSS HR (95% CI) | OS HR (95% CI) |
|-------------------------------|---------------------|-----------------------------|----------------|
| Schmid et al. 2007 [36]       | 5                   | 1.2 (1.1–1.3)               | 1.1 (1.05–1.3) |
| Six et al. 2008 [33]          | 5                   | 4.3 (0.9–13.7)              |               |
| Hefer et al. 2008 [28]        | 10                  | 1.81 (1.81–2.74)            | 1.81 (1.81–2.74) |
| Stephan et al. 2011 [23]      | 5                   | 1.2 (1.1–1.4)               | 1.4 (1.2–1.8)  |
| Dobrzycka et al. 2013 [27]    | 11.19               | 0.84 (0.72–2.84)            | 1.87 (0.58–2.87) |
| Nakamura et al. 2015 [21]     | 7                   | NM                          | 1.858 (0.644–5.357) |
| Zhang et al. 2015 [29]        | 10                  | 1.49 (1.096–2.027)          | 1.435 (1.023–2.013) |
| Lu et al. 2015 [31]           | 8                   | NM                          | 2.18 (1.3–3.67) |
| Li et al. 2015 [34]           | 8.2                 | 7.24 (3.27–16.02)           | NM             |
| Xiao et al. 2015 [26]         | 10                  | 1.88 (1.32–2.68)            | 1.95 (1.31–2.88) |
| Bodner–Adler et al. 2016 [19] | 5                   | NM                          | 1.238 (1.064–1.441) |
| Liu et al. 2017 [32]          | 10                  | NM                          | 1.005 (1.001–1.009) |
| He et al. 2018 [25]           | 10                  | NM                          | 3.03 (1.34–6.82) |
| Wang et al. 2019 [24]         | 3.135               | 1.423 (0.866–2.338)         | 2.081 (1.096–3.953) |
| Wang et al. 2020 [20]         | 5                   | NM                          | 2.208 (1.265–3.251) |
| An et al. 2020 [22]           | NM                  | 1.32 (0.49–3.14)            | 1.25 (0.84–1.81) |
| Terlikowska et al. 2020 [35]  | NM                  | NM                          | 1.22 (1.01–1.43) |
| Komura et al. 2020 [30]       | 7.6                 | 1.96 (1.1–3.57)             | NM             |
| Njoku et al. 2021 [37]        | 5.5                 | 1.13 (0.58–2.20)            | 1.68 (1.00–2.81) |

Abbreviations: DFS: disease-free survival; DSS: disease-specific survival; HR: HR (high vs. low); NM: not mentioned; OS: overall survival; PFS: progression-free survival; RFS: recurrence-free survival.

2.3. Extraction of Data and Evaluation of Quality. The data from the eligible studies were carefully examined by independent researchers YY, Y, RH, Z, H, Q and X. L. The data extracted mainly included: the first author, publication date, sample size, the cancer type, country, recurrence, average age, duration of follow-up, tumor pathologies, FIGO stage, cut-off value for CRP, and outcomes of patients (overall survival (OS), disease-free survival (DFS), recurrence-free survival (RFS), progression-free survival (PFS), and disease-specific survival (DSS)). The Newcastle-Ottawa Scale was also utilized to assess the overall quality of the publications included articles.

2.4. Statistical Analysis. The statistical analysis was carried out with the help of Stata 12.0 (StataCorp LP). The OR and 95% CI were used to assess the correlations between serum CRP and clinicopathological characteristics. To further understand the predictive significance of CRP, we used pooled HRs with 95% CI intervals to analyze the relationship between CRP and survival. Multivariate analysis was preferred based on results from univariate analysis. If not reported directly in the literature, the HR with 95% CI was extrapolated from the Kaplan–Meier curves. $\chi^2$ and $I^2$ tests were used to assess the heterogeneity across the articles. $p < 0.10$ or $I^2 > 50\%$ indicated significant heterogeneity between studies, and these studies were deemed to be the best for building a random-effects model, rather than a fixed-effects model, for estimating the pooled ORs/HRs. In addition, a one-way sensitivity analysis was carried out to determine the stability of the current findings. The Begg test and funnel plots were also used to determine whether or not there was a difference in publication bias across the publications included. Among these two-tailed statistical tests, $p < 0.05$ (95% CI) was regarded as statistically significant.

3. Results

3.1. Characteristics of Included Studies. A total of 19 eligible studies were included, involving 4062 patients (1230 patients diagnosed with cervical cancer (CC), 1546 with ovarian cancer (OC), 1219 with endometrial cancer (EC), and 67 with vulvar cancer (VC)) [19–36]. It should be noted that all patients included in these studies received surgical treatment. Their basic characteristics are shown in Tables 1 and 2. The patients were from various countries, including Austria [19, 23, 28, 33, 36], China [20, 22, 24–26, 29, 31, 32, 34], Poland [21, 27], Japan [30, 35], and the United Kingdom [37]. These studies were published between 2007 and 2021 and their sample sizes could be traced. Various treatments, like surgery, radiotherapy, chemotherapy, and chemoradiotherapy, were used. In the articles above, the cut-off values of CRP ranged from 3.135 to 10 mg/L. In addition, OS, DFS, DSS, PFS, and RFS were described in 15, 4, 2, 3, and 2 studies, respectively.

3.2. Clinicopathological Characteristics and CRP. FIGO stage (OR = 0.43, 95% CI: 0.19–1.00; Table 3) (Figure 2(a)) was related to elevated CRP level. Age (OR = 0.93, 95% CI:
Table 3: Association between CRP level and clinicopathological characteristics in gynecological cancer patients.

| Clinical parameters | Number of studies (number of patients) | OR (95% CI) | p value |
|---------------------|----------------------------------------|-------------|---------|
| Age                 | 4 (725)                                | 0.93 (0.69–1.25) | 0.346   |
| FIGO stage          | 4 (725)                                | 0.43 (0.19–1.00) | 0.001   |
| Grade               | 3 (615)                                | 0.74 (0.52–1.05) | 0.685   |
| Node                | 3 (618)                                | 0.91 (0.65–1.28) | 0.186   |

| Study                | ID | OR (95% CI) | %    | Weight |
|----------------------|----|-------------|------|--------|
| Lu Y (2015)          |    | 0.11 (0.05, 0.27) | 22.86|        |
| Wang W (2019)        |    | 0.41 (0.19, 0.88) | 24.52|        |
| Wang H (2020)        |    | 0.65 (0.34, 1.24) | 26.14|        |
| Kelechi Njoku (2021) |    | 0.98 (0.53, 1.81) | 26.48|        |
| Overall (I-squared = 81.5%, p = 0.001) |    | 0.43 (0.19, 1.00) | 100.00| |

NOTE: Weights are from random effects analysis

Figure 2: Forest plot of the association between CRP level and FIGO stage (a), OS (b), DFS (c), and PFS (d) in gynecologic cancers. FIGO, International Federation of Gynecology and Obstetrics; DFS, disease-free survival; OS, overall survival; PFS, progress-free survival.

0.69–1.25; Table 3), histological grade (OR = 0.74, 95% CI: 0.52–1.05; Table 3), and lymph node metastasis (OR = 0.91, 95% CI: 0.65–1.28; Table 3) were not associated with elevated CRP level.

3.3. Long-Term Outcomes and CRP. High CRP levels were associated with worse OS (HR = 1.40, 95% CI: 1.23–1.57; $I^2 = 79.5\%$, $p \leq 0.001$; Figure 2(b)), DFS (HR = 1.20, 95% CI: 1.12–1.28; $I^2 = 0.0\%$, $p = 0.719$; Figure 2(c)) and PFS (HR = 1.57, 95% CI: 1.30–1.98; $I^2 = 0.0\%$, $p = 0.587$; Figure 2(d)).

The subgroup analysis was based on groups that were stratified depending on the kind of cancer. There were statistically significant variations in the connection between CRP and OS of CC. (HR = 1.42, 95% CI: 1.19–1.64, $I^2 = 25.1\%$, $p = 0.229$; Figure 3(a)), OC (HR = 1.67, 95% CI: 1.03–2.31, $I^2 = 88.7\%$, $p \leq 0.001$; Figure 3(a)) and EC (HR = 1.15, 95% CI: 1.02–1.28, $I^2 = 13.7\%$, $p = 0.314$; Figure 3(a)). A further subgroup analysis based on the HR value found that, when HR was treated as a multivariate variable, a moderately significant connection was detected between CRP and OS (HR = 1.22, 95% CI: 1.10–1.33, $I^2 = 26.7\%$, $p = 0.235$; Figure 3(b)). A subgroup analysis also confirmed significant correlation of OS with preoperative (HR = 1.50, 95% CI: 1.23–1.77, $I^2 = 74.6\%$, $p \leq 0.001$; Figure 3(c)) and postoperative (HR = 1.31, 95% CI: 1.04–1.57, $I^2 = 68.9\%$, $p = 0.004$; Figure 3(c)) CRP. In the country-based subgroup analysis, significant correlations were observed between CRP and OS in western countries (HR = 1.39, 95% CI: 1.17–1.62, $I^2 = 76.3\%$, $p \leq 0.001$; Figure 3(d)) or eastern countries (HR = 1.57, 95% CI: 1.28–1.99, $I^2 = 38.6\%$, $p = 0.001$; Figure 3(d)).
### Figure 3: Analysis of subgroups for the association between CRP and OS. (a) Subgroup analysis based on cancer type. (b) Subgroup analysis based on HR. (c) Subgroup analysis based on serum CRP concentration measured before or after surgery. (d) Subgroup analysis based on country (Eastern or Western). (e) Subgroup analysis based on age. (f) Subgroup analysis based on the cut-off value of CRP. CRP: C-reactive protein.
1.18–1.96, \( I^2 = 66.2\% \), \( p = 0.003 \); Figure 3(d)). In the age-based subgroup analysis, a significant correlation between CRP and OS was found among older patients (\( \geq 55 \) years old) (HR = 1.84, 95% CI: 1.30–2.38, \( I^2 = 74.8\% \), \( p \leq 0.001 \); Figure 3(e)), or younger patients (\(< 55 \) years old) (HR = 1.31, 95% CI: 1.09–1.53, \( I^2 = 70.1\% \), \( p \leq 0.001 \); Figure 3(e)). In the CRP-based subgroup analysis, the correlation between CRP and OS was statistically significant (\( \leq 5 \) mg/L: HR = 1.28, 95% CI: 1.07–1.53, \( I^2 = 70.1\% \), \( p \leq 0.001 \); Figure 3(e)), >5 mg/L: HR = 1.75, 95% CI: 1.24–2.26, \( I^2 = 82.5\% \), \( p \leq 0.001 \); Figure 3(f)).

3.4. Publication Bias and Sensitivity Analysis. Using the pooled data, a sensitivity analysis was performed in order to determine the relative contribution of each study to the estimated outcomes from that data (Figure 4). We found that the heterogeneity was not significant among the included studies. There was no evidence of publication bias, suggesting that the findings of the meta-analysis were statistically credible.

4. Discussion
CRP is mainly synthesized by the liver under the action of some proinflammatory factors [38]. It plays an important role in innate immunity, complement activation, and immunoglobulin receptor binding. The close correlation between CRP and the occurrence of malignant tumors has been widely recognized.

A meta-analysis has shown that mortality increases in patients with high CRP levels, particularly those with gastrointestinal malignancies and renal malignancies [39]. On the one hand, chronic inflammation can increase the risk of cancer. On the other hand, proinflammatory mediators and factors are released in cancer patients undergoing nonspecific inflammatory responses [40]. These mediators and factors can promote tumor growth and metastasis. At the same time, nonspecific inflammatory mediators caused by tumor tissue necrosis or (and) local tissue damage can regulate and induce hepatocytes to synthesize a large amount of CRP, resulting in a secondary increase in serum CRP concentration. The
concentration of CRP not only reflects the degree of inflammatory response but also the malignancy of tumor phenotype and the possibility of metastasis [41]. According to the findings of this research, a rise in serum CRP levels is strongly associated with a higher FIGO stage, which is a significant prognostic factor.

IL-6 is produced by inflammatory processes, including cancer, and then, acts on the liver which produces C-reactive protein [42]. Based on these findings, it seems that serum CRP is a good alternative measure of IL-6 activity in cancer patients. IL-6 is a cytokine that modulates the biological activity of a wide range of cells, including cancer cells. IL-6 has a role in the host's immunological response as well as the development and differentiation of a variety of malignant tumors, according to the USA National Cancer Institute. It has been revealed that the IL-6R-JAK-STAT3 signaling pathway is involved in the promotion of cancer development and progression [43]. STAT proteins are a class of transcription factors that play an important part in the signaling pathways involving tyrosine kinases [44]. When STAT3 is activated continuously, it may enhance cell cycle progression, tumor invasion, tumor cell death, metastasis, tumor proliferation, and angiogenesis, among other things.

Host genetic variables, including inflammation-induced cytokines, are crucial in the etiology, development, and prognosis of cervical cancer, as well as other cancers. In a study of 215 cervical cancer patients, the level of serum CRP is closely related to tumor stage, lymphatic metastasis, and age, but not cell grade and tissue type. This suggests CRP as a valuable prognostic parameter for cervical cancer due to its close relationship with tumor-free survival and overall survival [45]. In a prospective study, serum CRP level increased within a few years before the diagnosis of ovarian cancer. In the group with high serum CRP levels (3 mg/L ≤ CRP < 10 mg/L), the risk of ovarian cancer increases about twice [46]. These results explain that elevated CRP levels are related to worse clinical outcomes, including DFS, PFS, and OS. A substantial connection was found between CRPs and OS in the subgroup analysis with a cut-off value of ≥5 mg/L for CRPs. It has been proven that as the level of CRP increases, the prognosis becomes poorer.

Therefore, we believe that CRP can be used to guide the personalized care of gynecological cancer and as a reference factor for postoperative recurrence risk assessment and adjuvant treatment.

It is worth noting some evident limitations of the current study. Patients with gynecologic malignancies had a wide range of characteristics, including cancer kind, stage, treatment plan, and follow-up month, all of which might have a significant influence on the aggregated findings. Second, the cut-off value for CRP was derived using previously published data, which may have shown some variability in the data. Third, this meta-analysis contained just 19 articles. For this reason, well-designed studies with high sample sizes should be done in the future to confirm our findings, as previously stated.

5. Conclusions
A high serum CRP level is associated with a poorer prognosis for gynecologic cancers. Serum CRP, an easily obtained indicator, may be widely used to help predict the prognosis of patients.

Data Availability
The data that are included in this article are made available from the corresponding author upon request.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Authors’ Contributions
YY. Y and RH. Z screened the title, abstract, and full text and wrote the manuscript. H. Q and X. L extracted the features of the included articles according to the Cochrane guidelines. All authors read and approved the final manuscript.

Acknowledgments
This work was supported by the National Natural Science Foundation of China. (82074478).

References
[1] B. Stewart and C. Wild, World Cancer Report 2020, International Agency for Research on Cancer, Lyon, France, 2020.
[2] A. Buskwofie, G. W. David, and C. A. Clare, “A review of cervical cancer: incidence and disparities,” Journal of the National Medical Association, vol. 112, no. 2, pp. 229–232, 2020.
[3] W. Q. Chen, R. S. Zheng, P. D. Baade et al., “Cancer statistics in China, 2015,” CA: A Cancer Journal for Clinicians, vol. 66, no. 2, pp. 115–132, 2016.
[4] C. Allemani, H. K. Weir, H. Carreira et al., “Global surveillance of cancer survival 1995–2009: analysis of individual data for 2567887 patients from 279 population-based registries in 67 countries (CONCORD-2),” The Lancet, vol. 385, no. 9972, pp. 977–1010, 2015.
[5] O. Raglan, I. Kalliala, G. Markozannes et al., “Risk factors for endometrial cancer: an umbrella review of the literature,” International Journal of Cancer, vol. 145, no. 7, pp. 1719–1730, 2019.
[6] V. Galic, T. J. Herzog, S. N. Lewin et al., “Prognostic significance of adenocarcinoma histology in women with cervical cancer,” Gynecologic Oncology, vol. 125, no. 2, pp. 287–291, 2012.
[7] H. David, “Rudolf Virchow and modern aspects of tumor pathology,” Pathology, Research & Practice, vol. 183, no. 3, pp. 356–364, 1988.
[8] C. Siemes, L. E. Visser, J. W. W. Coerbergh et al., “C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study,” Journal of Clinical Oncology, vol. 24, no. 33, pp. 5216–5222, 2006.
[9] S. Lee, J. W. Choe, H. K. Kim, and J. Sung, “High-sensitivity C-reactive protein and cancer,” Journal of Epidemiology, vol. 21, no. 3, pp. 161–168, 2011.
[10] J. Lu, B. B. Xu, Z. F. Zheng et al., “CRP/prealbumin, a novel inflammatory index for predicting recurrence after radical resection in gastric cancer patients: post hoc analysis of a randomized phase III trial,” Gastric Cancer, vol. 22, no. 3, pp. 536–545, 2019.

[11] K. H. Allin and B. G. Nordestgaard, “Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer,” Critical Reviews in Clinical Laboratory Sciences, vol. 48, no. 4, pp. 155–170, 2011.

[12] P. Allavena, C. Garlanda, M. G. Borrello, A. Sica, and A. Mantovani, “Pathways connecting inflammation and cancer,” Current Opinion in Genetics & Development, vol. 18, no. 1, pp. 3–10, 2008.

[13] I. Gockel, K. Dirksen, C. M. Messow, and T. Jungher, “Significance of preoperative C-reactive protein as a parameter of the peri-operative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus,” World Journal of Gastroenterology, vol. 12, no. 23, pp. 3746–3750, 2006.

[14] K. Hashimoto, Y. Ikeda, D. Korenaga et al., “The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma,” Cancer, vol. 103, no. 9, pp. 1856–1864, 2005.

[15] D. C. McMillan, K. Canna, and C. S. McArdle, “Systemic inflammatory response predicts survival following curative resection of colorectal cancer,” British Journal of Surgery, vol. 90, no. 2, pp. 215–219, 2003.

[16] D. J. F. Brown, R. Milroy, T. Preston, and D. C. McMillan, “The relashion between an inflammation-based prognostic score (Glasgow Prognostic Score) and changes in serum biochemical variables in patients with advanced lung and gastrointestinal cancer,” Journal of Clinical Pathology, vol. 60, no. 6, pp. 705–708, 2007.

[17] M. M. Meyer, L. Brandenburg, H. Hudel et al., “Who is afraid of CRP? Elevated preoperative CRP levels might attenuate the increase in inflammatory parameters in response to lung cancer surgery,” Journal of Clinical Medicine, vol. 9, no. 10, p. 3340, 2020.

[18] J. Lu, B. B. Xu, Z. Xue et al., “Perioperative CRP: a novel inflammation-based classification in gastric cancer for recurrence and chemotherapy benefit,” Cancer Medicine, vol. 10, no. 1, pp. 34–44, 2021.

[19] B. Bodner-Adler, O. Kimberger, C. Schneidinger, H. Köbl, and K. Bodner, “Prognostic significance of pre-treatment serum C-reactive protein level in patients with adenocarcinoma of the uterine cervix,” Anticancer Research, vol. 36, no. 9, pp. 4691–4696, 2016.

[20] H. Wang, M. S. Wang, Y. H. Zhou, J. P. Shi, and W. J. Wang, “Prognostic Values of LDH and CRP in Cervical Cancer,” Oncotargets and Therapy, vol. 13, pp. 1255–1263, 2020.

[21] K. Nakamura, T. Nishida, T. Haruma et al., “Pretreatment platelet-lymphocyte ratio is an independent predictor of cervical cancer recurrence following concurrent chemoradiation therapy,” Molecular and Clinical Oncology, vol. 3, no. 5, pp. 1001–1006, 2015.

[22] Q. An, W. Liu, Y. Yang, and B. Yang, “Preoperative fibrinogen-to-albumin ratio, a potential prognostic factor for patients with stage IB-IIA cervical cancer,” BMC Cancer, vol. 20, no. 1, p. 691, 2020.

[23] S. Polterauber, C. Grimm, R. Zeillinger et al., “Association of C-reactive protein (CRP) gene polymorphisms, serum CRP levels and cervical cancer prognosis,” Anticancer Research, vol. 31, no. 6, pp. 2259–2264, 2011.
[38] T. P. Erlinger, E. A. Platz, N. Rifai, and K. J. Helzlsouer, “C-reactive protein and the risk of incident colorectal cancer,” JAMA, vol. 291, no. 5, pp. 585–590, 2004.
[39] S. H. Lee, K. H. Kim, C. W. Choi et al., “Reduction rate of C-reactive protein as an early predictor of postoperative complications and a reliable discharge indicator after gastrectomy for gastric cancer,” Ann Surg Treat Res, vol. 97, no. 2, pp. 65–73, 2019.
[40] E. Shacter and S. A. Weitzman, “Chronic inflammation and cancer,” Oncology, vol. 16, no. 2, p. 217, 2002.
[41] J. M. Jones, N. C. McGonigle, M. McAnespie, G. W. Cran, and A. N. Graham, “Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer,” Lung Cancer, vol. 53, no. 1, pp. 97–101, 2006.
[42] O. Fiala, P. Hosek, M. Pesek et al., “Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed,” Neoplasma, vol. 64, no. 4, pp. 605–610, 2017.
[43] S. Bacha, A. Sghaier, S. Habibech et al., “Combined C-reactive protein and Neutrophil to Lymphocyte ratio use predict survival in non-small-cell lung cancer,” Tunisie Medicale, vol. 95, no. 12, pp. 229–235, 2017.
[44] M. Kogo, T. Sunaga, S. Nakamura et al., “Prognostic index for survival in patients with advanced non-small-cell lung cancer treated with third-generation agents,” Chemotherapy, vol. 62, no. 4, pp. 239–245, 2017.
[45] S. Polterauer, C. Grimm, C. Tempfer et al., “C-reactive protein is a prognostic parameter in patients with cervical cancer,” Gynecologic Oncology, vol. 107, no. 1, pp. 114–117, 2007.
[46] M. A. McSorley, A. J. Alberg, D. S. Allen et al., “C-reactive protein concentrations and subsequent ovarian cancer risk,” Obstetrics & Gynecology, vol. 109, no. 4, pp. 933–941, 2007.